Cognetivity Neurosciences to partner with Oxford University in study of smartphone-based remote cognitive assessment

Research will utilise Cognetivity’s Integrated Cognitive Assessment (ICA) technology to study potential early-stage cognitive decline in individuals at risk of developing dementia

 

Vancouver, BC  – Decemeber 1, 2020 Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (FWB: 1UB) (OTCQB: CGNSF) today announced that it will be collaborating with researchers at Oxford University to investigate the use of its Integrated Cognitive Assessment (ICA) in monitoring the cognition of individuals at risk of developing dementia. Participants in the study will take the ICA remotely via their smartphones, offering further insight into the potential of Cognetivity’s digital tool to enhance early-stage dementia diagnosis.

 

The collaborative project has arisen through the organisations’ shared membership of the prestigious Dementias Platform UK (DPUK) network. A public-private partnership, DPUK counts several of the UK’s highest-ranked universities, medical technology companies and some of the world’s largest pharmaceutical companies among its members, and has received £53 million in funding from the Medical Research Council (MRC) since its launch in 2014. DPUK aims to accelerate research into the origins of dementia by forging relationships between academia and industry, providing a single, shared data repository, and enhancing recruitment in clinical studies via its extensive Great Minds Register of volunteers, from which participants in the Cognetivity-Oxford study will be recruited.

 

Although dementia is the leading cause of death in England and Wales , its development remains poorly understood and, with traditional cognitive testing methods, patients rarely manage to obtain a diagnosis early enough to receive the maximal benefits of treatment. The study aims to break new ground, using remote, smartphone-based assessment with a view to measuring cognitive decline associated with the earliest stages of disease. In this study, researchers intend to recruit cognitively healthy participants aged 50 and up who may be at risk of cognitive impairment or who are subjectively concerned about their cognition.

 

The study will be led by Dr. Ivan Koychev, a Senior Clinical Researcher and Specialist Consultant Neuropsychiatrist at Oxford University and the National Health Service, who expressed his enthusiasm for the project. “Dementia is one of the biggest healthcare challenges facing our generation. We now know that the process leading to it starts 15-20 years before symptoms. The healthcare system is not geared up to identify the individuals in its preclinical stages and that is why we are looking to digital technology as a scalable means to point to dementia risk.” Dr. Koychev said. He further states, “Cognetivity’s ICA has great potential to contribute to this. With its unique approach to cognitive testing, it could pave the way for accurate, early-stage dementia diagnosis that, through remote assessment, is in line with what is required for the future of clinical practice and increases accessibility, particularly among populations under-represented in research studies and also Covid-19 affected populations.”

 

“It’s not hard to see how this kind of testing could revolutionize patient care,” agreed Dr. Sina Habibi , CEO of Cognetivity. “If a tool such as the ICA were available to the millions of people who are at risk, or belong to the so-called “the worried well”, to be able to regularly and accurately check up on their cognition, there would be many more healthy individuals feeling reassured and many more people with dementia accessing treatment as early as possible – a fantastic result. At the same time, the healthcare system would benefit from the cost savings associated with a reduction in unnecessary, in-person cognitive assessments. As ever, the prospect of empowering clinical excellence is what is motivating us as we join forces with Oxford and DPUK in carrying out this research.”

 

About Cognetivity Neurosciences Ltd.

 

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.

 

For more information, please visit: www.cognetivity.com

 

ON BEHALF OF THE BOARD
“Sina Habibi”

Sina Habibi
Chief Executive Officer and Director

 

FORWARD-LOOKING STATEMENTS:

 

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

 

The Exchange does not accept responsibility for the adequacy or accuracy of this release.

 

SOURCE Cognetivity Neurosciences Ltd

Sign Up & Get FREE News Alerts From FNM Today!